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Abstract
Benign hereditary chorea (BHC) is a childhood-onset, hyperkinetic movement disorder normally with little progression of motor symptoms into adult life. The
disorder is caused by mutations to the NKX2.1 (TITF1) gene and also forms part of the ‘‘brain–lung–thyroid syndrome’’, in which additional developmental
abnormalities of lung and thyroid tissue are observed. In this review, we summarize the main clinical findings in ‘‘classical’’ BHC syndrome and discuss more recently
reported atypical features, including non-choreiform movement phenotypes. We highlight additional non-motor characteristics such as cognitive impairment and
psychiatric symptoms, while discussing the evidence for BHC as a developmental disorder involving impaired neural migration and other multisystem developmental
abnormalities. Finally, we will discuss the efficacy of available therapies in both affected pediatric and adult cohorts. Delineation of the BHC disease spectrum will no
doubt expand our understanding of this disorder, facilitating better targeting of genetic testing and establish a framework for future clinical trials.
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Introduction
Benign hereditary chorea (BHC) (MIM 118700) is a rare childhood-
onset movement disorder characterized predominantly by non-
progressive chorea. The first familial description reported a 32-member,
five-generation African-American family from Mississippi, USA, in
which the probands, two teenage brothers, presented with childhood-
onset chorea and delayed motor development.1
A number of families with a similar phenotype to these original
cases and an autosomal dominant pattern of inheritance were
reported over subsequent years, although their descriptions were
frequently heterogenous with atypical features such as dystonia,
tremor, and myoclonus described.2–4 This led some to question the
validity of BHC as single diagnosis and specific disease entity.5
Furthermore, 11 families, originally considered to have a clinical
diagnosis of BHC, were later confirmed to have different genetically
confirmed diagnoses, including Huntington’s disease (HD), myoclonus
dystonia (MD), and ataxia telangiectasia (AT). This study also
demonstrated the difficulties in classifying movement disorders, with
significant discrepancy between experts when reviewing videotaped
examinations.5
In 2000, genetic analysis of a four-generation Dutch family in tandem
with another of the originally described BHC families, established
linkage to a disease locus on the long arm of chromosome 14.2,6,7
Recombination analysis of six further families reduced the critical
region to 8.4cM (14q13.1-q21.1). Using chromosomal markers and
two-color fluorescence in situ hybridization (FISH) a de novo 1.2-Mb
deletion involving the NKX2.1 gene, also known as TITF1, TTF1, and
TEBP, was identified.8 Breedveld et al.9 confirmed further NKX2.1
variants in four additional unrelated BHC families, in whomwhole gene
deletion (WGD), frameshift, and missense mutations were identified. At
the same time, NKX2.1 mutations were reported in a cohort of five
pediatric patients with hypothyroidism and ongoing symptoms, despite
adequate thyroxine replacement.10 The NKX2.1 clinical spectrum
appeared to therefore extend beyond a pure neurological phenotype.
In this review, we discuss the spectrum of clinical, genetic, and
pathological features considered to be typical of BHC, while also
considering more recent reports that expand the spectrum of the
disorder (Figure 1). We also discuss the current evidence for the
physiological role of NKX2.1 protein, putative pathogenic disease
mechanisms, and the relative efficacy of current treatment strategies.
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Methods
We performed a systematic literature search of the PUBMED
database using the key words ‘‘benign hereditary chorea’’, ‘‘brain–
lung–thyroid syndrome’’, ‘‘NKX2.1’’, ‘‘TITF1’’, ‘‘TTF1’’, and
‘‘TEBP ’’. There was no restriction on year of publication but only
those published in English and in peer-reviewed journals were
included.
Epidemiology
A single epidemiological study of the Welsh population estimated
the prevalence of BHC to be ,1:500,000 in 1978, although this is
widely considered to be an underestimate due to poor recognition of
subtle choreiform phenotypes.11 Other studies have reported that, in
addition to gender-dependent variation in penetrance (100% in males,
75% in females), there is significant inter- and intrafamilial variation of
clinical phenotypes.12 Larger cohort studies have also suggested that
females are more commonly affected than males (0.64:0.46), whether
additional genetic or environmental factors contribute to this observed
gender difference remains undetermined.13,14
Clinical description
Motor features
Classical motor symptoms in BHC include mild to moderate
hypotonia with delayed motor milestones in infancy. Onset of chorea is
usually in early childhood (median age 2.5–3 years), although this is likely
to be younger due to relatively late recognition of the movement disorder
phenotype.13–15 The chorea is often generalized, affecting all body parts
(face, limbs, trunk) and tends to worsen with stress or excitement.16 In the
majority of cases the chorea will remain stable, or improve during
adolescence and early adulthood, with other movement disorders such as
myoclonus becoming more prevalent and disabling.12,13
Other types of movement disorder have also been reported in
NKX2.1 mutation-positive cases (either in isolation or in conjunction
with chorea) and include ataxia, upper limb intention tremor, limb
dystonia, and motor and vocal tics.13,14,17,18 Facial apraxia and axial
dystonia have also been described, although in both cases, genetic
confirmation was not possible as the clinical description pre-dated
NKX2.1 gene identification.19,20 More recently, recurrent drop attacks
Figure 1. Diagram of the ‘‘Classical’’ Features of Benign Hereditary Chorea and Expanding Clinical Phenotype. Each ring, brain (red), lung (green),
and thyroid (blue), represents a body system involved in the classical brain–lung–thyroid triad. The most common clinical features are listed within each ring. Other
clinical features increasingly recognized in association with NKX2.1mutations are listed outside the rings. ADHD, Attention Deficit Hyperactivity Disorder; Brain–Lung–
Thyroid, Overlapping clinical phenotypes involving the complete brain–lung–thyroid clinical spectrum; OCD, Obsessive–Compulsive Disorder.
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and frequent falls have been reported, often resulting in significant
trauma. In one of these cases, electroencephalography during a typical
episode demonstrated that these features were not associated with ictal
epileptiform activity, suggesting that they were a consequence of the
movement disorder phenotype, rather than an epileptic event.
17,21
Speech disturbance has been consistently reported in BHC patients.
Dysarthria is most frequently reported, evident in 40% of cases from a
single case series.14,22 Stammer as well as slow, slurred, stuttering, and
explosive speech have also each been described in single cases.18,23,24
Interestingly, in the largest longitudinal cohort studied to date, no
dysarthria was described but three unrelated cases were described as
having vocal tics.13
Cognition
Cognitive status in those with BHC has historically been considered
normal, and previously postulated to be an integral marker in
differentiating this form of chorea from more neurodegenerative forms
associated with cognitive impairment, e.g. Huntington’s disease.16
However, prior to NKX2.1 gene discovery, several reports documented
reduced IQ in those with clinical BHC syndrome, with one study
finding average IQ to be 10 points lower in motor affected individuals
than unaffected family members.2,25,26 Subsequent studies have
documented variable findings on cognitive assessment. Although
some, using standardized scales (Mini Mental State Examination
[MMSE] and Wechsler Adult Intelligence Scale - Revised [WAIS-R]),
reported reduced levels of cognitive functioning, others have described
children performing academically above that expected for their
age.17,23 Two recent case series have also demonstrated conflicting
results. We reported grossly normal levels of intellect, gauged by
attendance in mainstream education, while Gras et al identified
learning difficulties in 20 out of 28 reported cases.13,14 Of these 20
patients, 14 underwent formal assessment. Within this subgroup, three
were considered to have mental retardation (IQ , 70), three had
borderline IQ levels (70–80) and eight were found to have IQs within
normal limits (IQ . 80). The other six cases were historically reported
to have learning difficulties during the course of their education,
though no formal cognitive assessment was performed. It therefore
remains to be determined whether these deficits in cognitive function
reflect an integral part of the BHC phenotype or a secondary
consequence of social embarrassment and isolation resulting in
reduced periods of education.
Psychiatric symptoms
Depression, apathy, psychosis, and prolonged inpatient psychiatric
admission were all described in early reports of patients with BHC
clinical syndrome.2,27 Psychosis, schizophrenia, post-partum psychosis,
obsessive–compulsive disorder (OCD), and attention deficit hyper-
activity disorder (ADHD) have all been reported in patients with
NKX2.1 mutations.14,18,28,29 The recent large, longitudinal French
study found seven out of 28 mutation-positive cases to have a diagnosis
of ADHD, of whom nearly all (six out of seven) had IQ levels within
the normal range.13
Brain–lung–thyroid spectrum and other clinical features
The combination of brain, lung, and thyroid involvement was first
described in a single case involving a contiguous NKX2.1 gene deletion
in which the patient had neonatal respiratory failure, a high serum
thyrotropin concentration, motor delay, hypotonia, and truncal
ataxia.30 However, it wasn’t until description of a clinically similar
case two decades later that the term brain–lung–thyroid syndrome was
coined.31 Typical respiratory symptoms include neonatal or infant
respiratory distress syndrome, frequently resulting in mechanical
ventilation followed by recurrent pulmonary infections, development
of obstructive airways disease, and chronic interstitial lung disease.
Thyroid dysfunction usually takes the form of congenital hypothyroid-
ism, which in a proportion of cases may be due to thyroid agenesis.16
Two larger case series have demonstrated 30–36% patients have
symptoms involving all three organs, 32–40% with brain and thyroid
involvement, and 20–21% with brain and lung disease alone.13,14
However, both cohorts only recruited participants from neurology/
movement disorder outpatient clinics with likely ascertainment bias. In
reality, the full triad of brain–lung–thyroid symptoms seems to be
evident in up to 50% of cases with NKX2.1 mutations, while
involvement of brain and thyroid appears to consistently involve
30% of all cases.15,32 It is postulated that brain–lung–thyroid syndrome
and BHC may represent part of a continuous spectrum of disorders
and that the associated lung and thyroid features were not recognized
or investigated in early descriptions of the BHC clinical syndrome.12
Other clinical features have also been consistently reported,
including developmental abnormalities of the urinary tract, such as
hypospadias, vesico-urethral reflux, megabladder, duplex kidney, and
recurrent urinary tract infections.3,14,28,33 Others have reported single
cases manifesting hypo- or oligodontia,34 hypoparathyroidism,34 short
stature, webbed neck,18 joint hypermobility,22 sensorineural hearing
loss,35 seizures,36 optic nerve glioma,2 growth hormone deficiency,
visual disturbance, pes cavus, and kyphosis.14 It is currently uncertain
whether these features are disease related or incidental findings.
Links with malignancy
An increasing number of case reports describe malignancy in those with
NKX2.1 mutations. Lung carcinoma is most frequently reported, often
preceded by a history of pulmonary disease such as alveolar proteinosis,
asthma, or recurrent respiratory tract infections.13,18,31,37 In addition, two
terminal cases of leukemia and a single case of small cell bladder
carcinoma have also been described.22,38 Interestingly in a mouse model of
lung carcinoma, reduced TITF1 signaling contributes to tumor formation.
Gene overexpression has also been recognized in a broad spectrum of
malignancy subtypes including lung, thyroid, and prostate.39 More
recently, copy number variant analysis in lung adenocarcinoma led to
the suggestion of 14q13.3 amplification as a candidate proto-oncogene.40
Clinical indications for NKX2.1 testing and differential diagnosis
NKX2.1 testing should be considered in all those with a history of
neonatal hypotonia, motor developmental delay, and early-onset
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hyperkinetic movement disorder with predominant chorea and/or
dystonia. Clearly, early evidence of comorbid lung or thyroid
symptoms would serve to reinforce the importance of genetic testing.
However, these neurological features (in the presence of normal
cerebral magnetic resonance imaging) are common to a number of
other genetically determined movement disorders that would need to
be considered in the clinical differential diagnosis. Those to consider
would include myoclonus dystonia (particularly those with SGCE
mutations), given the difficulties in discriminating distal low amplitude
myoclonus and fine choreiform movements.41 Allan–Herndon–Dudley
syndrome, caused by SLC16A2 mutations, is a rare X-linked
hyperkinetic movement disorder. Its presentation frequently mirrors
that of BHC with initial hypotonia and subsequent development of
involuntary limb movements, frequently with dystonia.42 Finally,
autosomal dominant inherited adenylate cyclase-5 (ADCY5) mutations
have recently been identified in a number of families presenting with
early-onset chorea and dystonia, and will become an increasingly
important differential diagnosis in those with infancy-onset hyperki-
netic movement disorders.43
Imaging
Although cerebral imaging is normal in the majority of NKX2.1
mutation-positive cases, a variety of structural and enhancement
anomalies of uncertain significance have also been reported. These
have included ventricular dilatation, empty sella, bilateral pallidal
hyperintensity, and cystic masses in the pituitary and sella tur-
cica.10,14,23,44 Volumetric analysis of two mutation-positive cases found
bilateral reduction of striatal volumes, while magnetic resonance
spectroscopy identified altered myoinositol, creatine, and N-acetyl-
aspartate levels.45 Single-photon emission computed tomography scans
of two pediatric cases found reduced technetium-99 uptake in the basal
ganglia, while positron emission tomography (PET) studies of
dopamine transmission demonstrated reduced post-synaptic D2
receptor function.37,46 Although neurodegeneration is not considered
to occur in those with NKX2.1 mutations, fludeoxyglucose-PET
findings have been inconsistent in a small number of cases
demonstrating both normal and reduced cortico-striatal glucose
metabolism, the latter often being a feature observed in neurodegen-
erative forms of chorea such as Huntington’s disease.28,38 Overall,
these imaging findings are predominantly from single case reports or
small case series, so their relevance to NKX2.1-related disease remain
uncertain and may represent incidental findings. Future studies,
involving larger cohorts, using standardized imaging techniques, are
required before conclusions can be drawn regarding the specificity of
radiological findings.
Treatment
There are currently no consensus nor formal guidelines for the
treatment of chorea in patients with BHC. Multiple reports have
described single cases treated with a variety of agents including
trihexyphenidyl, corticosteroids, sodium valproate, propranolol, ropi-
nirole, and sulpiride, each with varying results.14,32,46 Levodopa has
been the most consistent in providing symptomatic improvement
(relatively high doses of 7–9 mg/kg/day), predominantly when given
during childhood, and in conjunction with physiotherapy.21,22,47 Cases
in which there has been little response to L-dopa have tended to use
lower levodopa doses, principally limited due to tolerability.13,14
Tetrabenazine also led to motor improvements in five cases at doses of
0.5 mg/kg/day in children and 37.5 mg/day in adults. Cessation of a
75 mg/day dosage in one case led to worsening of chorea and
disturbances to sleep and behavior.13,28 Olanzapine, for treatment of
psychosis, improved chorea in a single NKX2.1 mutation-positive case,
while in another the motor symptoms were left unchanged.18
Trihexyphenidyl and clonazepam have also been considered effective,
each in single cases, although neither led to complete resolution of
motor symptoms.14
Molecular genetics and pathophysiology
Gene function
NKX2.1 belongs to the natural killer gene family of highly conserved
homeodomain-containing transcription factors. The gene comprises
three coding exons giving rise to five transcripts. The two most
common isoforms are 371 and 401 amino acids in length
(ENST00000498187 and ENST00000354822) differing only in their
N-terminal sequences.48 The majority of pathogenic mutations lead to
protein truncation, either before or within the DNA-binding domain,
preventing DNA binding, and lead to loss-of-function.9In vitro studies
have demonstrated that the mutant protein has a dominant-negative
effect on transcriptional activity of the wild-type protein, suggesting
that the clinical phenotype is due to NKX2.1 haploinsufficiency.15,29
NKX2.1 mutations
A broad spectrum of NKX2.1 mutations and diverse clinical
phenotypes has been reported to date (Table 1, Figure 2).
A correlation between phenotype severity and type of mutation has
been postulated. Larger contiguous gene deletions have been
associated with a more severe spectrum of the brain–lung–thyroid
triad (often with additional clinical characteristics), while point
nonsense mutations, affecting the terminal regions of the protein, are
reported in those with a milder clinical phenotype.16 However, this
genotype–phenotype association is not seen in all cases, suggesting that
there may be other contributory environmental and/or epigenetic
factors.13,14 NKX2.1 mutations also demonstrate considerable intrafa-
milial variability, with severity of the movement disorder ranging from
significant to those with minimal functional impairment. There may
also be individual heterogeneity in the expression of other motor and
non-motor features between members of the same kindred.49 A full
summary of all known mutations and clinical features of cases with
contiguous gene deletions involving NKX2.1 is shown in Table 1 and
Figure 2.
It is likely that BCH is genetically heterogeneous. In four families
described in the original paper by Breedveld et al.,8 neither a NKX2.1
mutation nor linkage to chromosome 14 was identified. Genetic linkage
analysis of two unrelated Japanese families, each demonstrating an
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Table 1. Genotype and Clinical Phenotype of Reported Whole Gene Deletions Involving NKX2.1
Authors Year of
Publication
Deletion size and
Chromosomal
Location*
Genes
Involved1
Organ Involvement Additional
Clinical
CharacteristicsBrain Lung Thyroid
Devriendt et al.30 1998 ,13cM deletion
involving 14q13-
q21
NKX2.1, PAX9 Hypotonia,
truncal ataxia,
motor DD
RDS, mechanical
ventilation
Congenital
hypothyroidism
Nil observed
Iwatani et al. (1)62 2000 14q12-q13.3 NKX2.1, PAX9 Motor DD Bronchiolitis,
recurrent RTI,
RDS
Congenital
hypothyroidism
Feeding difficulties, failure to
thrive, microcephaly, hearing
loss, cognitive impairment,
dysmorphic facial features (e.g.
hypertelorism, high arched
palate), lower limb
contractures
Iwatani et al. (2)62 2000 14q12-q13.3 NKX2.1, PAX9 Motor DD Died of
respiratory
failure aged 3
years
Nil observed Feeding difficulties, failure to
thrive, microcephaly, hearing
loss, cognitive impairment
Breedveld et al.9 2002 1.2Mb NKX2.1, MBIP,
NKX2.8, PAX9,
SLC25A21
Chorea Nil observed Nil observed Nil observed
Krude et al.10 2002 14q11.2-q13.3 NKX2.1 Severe choreo-
athetosis
RDS, recurrent
RTI
Thyroid
hypoplasia
Nil observed
Devos et al. (1)34 2006 0.9Mb NKX2.1, MBIP,
NKX2.8, PAX9,
SLC25A21, MIPOL1
Chorea,
hypotonia
Nil observed Hypothyroidism Diarrhea
Devos et al. (2)34 2006 0.9Mb NKX2.1, MBIP,
NKX2.8, PAX9,
SLC25A21, MIPOL1
Chorea, motor
DD, hypotonia,
cerebellar signs
Interstitial
pneumonia
Hypothyroidism Diarrhea, malabsorption,
osteoporosis,
hypoparathyroidism, dry eyes
Devos et al. (3)34 2006 0.9Mb NKX2.1, MBIP,
NKX2.8, PAX9,
SLC25A21, MIPOL1
Chorea, motor
DD, hypotonia,
cerebellar signs
Interstitial
pneumonia
Hypothyroidism Diarrhea, malabsorption,
osteoporosis, dry eyes
Carre et al.15 2009 14q13 NKX2.1 Ataxia, motor
DD
RDS, mechanical
ventilation,
Recurrent RTI
Congenital
hypothyroidism
Mental retardation, impaired
saccadic eye movements,
absent corpus callosum
Accornero
et al.63
2010 1.2Mb NKX2.1, MBIP,
NKX2.8, PAX9,
SLC25A1
Chorea Nil observed Subclinical
hypothyroidism
Duplication of pituitary stalk
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Table 1. Continued
Authors Year of
Publication
Deletion size and
Chromosomal
Location*
Genes
Involved1
Organ Involvement Additional
Clinical
CharacteristicsBrain Lung Thyroid
Uematsu et al.64 2012 2.6Mb deletion
involving 14q12-
q13
NKX2.1 Motor DD,
choreoathetosis
Recurrent RTI Nil observed Bilateral reduced cerebral
blood flow in basal ganglia
(especially caudate nucleus) on
ECD-SPECT imaging
Gras et al. (1)13 2012 13.8Mb deletion
involving
14q13.2-q22.1
NKX2.1, MBIP,
PAX9, SLC25A21,
MPOL1, FOXA1,
SEC23A, GEMIN2,
TRAPPC6B, CTAGE5,
FBXO33, LRFN5,
FSCB, C14orf28,
KLHL28, FAM179B,
PRPF39, FKBP3,
FANCM, MDGA2
Chorea,
hypotonia
Nil observed Nil observed Nil observed
Gras et al. (2)13 2012 6.2-Mb deletion
involving
14q13.2-q21.2
NKX2.1, MBIP,
PAX9, SLC25A21,
MPOL1, FOXA1,
SEC23A, GEMIN2,
TRAPPC6B,
CTAGE5, FBXO33
Chorea,
hypotonia
Nil observed Hypothyroidism Learning difficulties, ADHD
Gras et al. (3)13 2012 0.3-Mb deletion
involving 14q13.3
NKX2.1, MBIP,
PAX9
Chorea Nil observed Hypothyroidism Learning difficulties, ADHD
Dale et al.65 2012 3.27-Mb deletion
(Chr
14:35,327,739-
38,602,335)
NKX2.1, PAX9,
MIPOL1, SEC23A
Motor DD, gait
disturbance
Nil observed Nil observed Mild intellectual disability,
ligament laxity, oligodontia
Teissier et al.66 2012 14q13.3 NKX2.1 Chorea,
dystonia, gait
disturbance
COPD Congenital
hypothyroidism
Nil observed
Teissier et al.66 2012 14q13.3 NKX2.1 Chorea,
hypotonia,
ataxia
Nil observed Congenital
hypothyroidism
Dysmorphic features:
hexadactyly, arched palate
Hamvas
et al. (1)67
2013 14q13.1-q21.1 NKX2.1 Hypotonia,
motor DD,
ataxia
Hypoxia,
recurrent RTI,
pneumathoraces
Hypothyroidism Absent corpus callosum
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Table 1. Continued
Authors Year of
Publication
Deletion size and
Chromosomal
Location*
Genes
Involved1
Organ Involvement Additional
Clinical
CharacteristicsBrain Lung Thyroid
Hamvas et al.
(2)67
2013 14q13.3 NKX2.1 Ataxia, motor
DD
Recurrent
infections
Hypothyroidism Behavioral difficulties
Hamvas et al.
(3)67
2013 14q13.3-q21.1 NKX2.1 Hypotonia, DD,
ataxia
RDS, PH, RTI,
oxygen therapy
Congenital
hypothyroidism
Language delay
Hamvas et al.
(4)67
2013 14q13.3-q21.1 NKX2.1 Hypotonia,
developmental
delay
RDS, PH Congenital
hypothyroidism
Microcephaly, language delay
Hamvas et al.
(5)67
2013 Deletion of
exons 1 & 2
NKX2.1 Hypotonia,
motor DD,
ataxia
Severe RDS Congenital
hypothyroidism
Language delay
Peall et al. (1)14 2014 0.36Mb deletion
(Chr14:36,924,
171-37,283,221)
SFTA3, NKX2.1,
BX161496,
NKX2.8, PAX9,
SLC25A21
Hypotonia,
dystonia, motor
DD
Nil observed Nil observed Nil observed
Peall et al. (2)14 2014 4.7Mb deletion
(Chr14:35,581,
654-40,301,792)
RALGAPAI, BRMS1L,
MBIP, SFTA3,
NKX2.1, NKX2.8,
PAX9, SLC25A21,
MIPOL1, TTC6,
SSTR1, CLEC14A,
SEC23A, GEMIN2,
TRAPPC6B, MIA2,
CTAGE5, FBX033
Hypotonia,
motor DD
Recurrent RTI Congenital
hypothyroidism
Growth hormone deficiency,
visual impairment
ADHD, Attention Deficit Hyperactivity Disorder; COPD, Chronic Obstructive Pulmonary Disease; DD, Developmental delay; ECD-SPECT, Ethyl Cysteinate Dimer-Single-photon Emission Computed
Tomography; PH, Pulmonary Hypertension; RDS, Respiratory Distress Syndrome; RTI, Respiratory Tract Infections.
1Information regarding deletion size, chromosomal location and genes involved is given is as much detail as is available from each publication. The numbers in brackets in column one indicate individual,
sequential cases when a single publication has reported multiple individuals.
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autosomal dominant pattern of inherited, slowly progressive chorea,
has suggested an alternative genetic locus on chromosome 8 (8q21.3-
q23.3), and named benign hereditary chorea 2 (BHC2).50 Interestingly,
the motor phenotype in both families differed somewhat from classical
BHC, namely with onset of disease in adulthood and slowly progressive
chorea. Furthermore, brain post-mortem analysis in one affected
individual, who had died from a respiratory tract infection, revealed
degeneration of the striatum and cerebral white matter together
with evidence of a tauopathy similar to that seen in progressive
supranuclear palsy.51
Animal models
Mouse expression studies reveal complex NKX2.1 expression during
embryonic development, with transcription of the gene evident in the
forebrain, thyroid, and developing lungs.52 NKX2.1 expression occurs
early in brain development, in the progenitor and post-mitotic cells of
the rostrobasal telencephalon, by the 11th somite stage.53 A NKX2.1
null knockout (KO) mouse model has no abnormal motor phenotype
in its heterozygous form but NKX2.1–/– homozygous mice died at birth
with absent lungs, pituitary, thyroid gland, and multiple abnormalities
of the ventral forebrain.54
The rostrobasal telencephalon later develops into several structures
including the medial ganglionic eminence (MGE), a precursor of the
globus pallidus. NKX2.1 has been found to facilitate migration of
striatal interneurons from the MGE to the lateral ganglionic eminence,
which later forms the striatum. These neurons then migrate to the
cortex and form predominantly gamma-aminobutyric acid and
calbindin expressing neurons. Failure of development of the MGE
prevents migration of cholinergic neurons to the pallidum and
ultimately to the striatum.55 Butt et al.56 investigated the role of
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Figure 2. Schematic Representation of NKX2.1 Missense, Frameshift, and Stop Codon Mutations Reported in the Published Literature to Date.
Different reported NKX2.1 mutations are represented, and nucleotide changes and protein changes are displayed. Stop codon mutations (green) and splice-site mutations
(purple) are located below the gene. Missense mutations (orange) and frameshift mutations (blue) are located above the gene.
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TTF1 during embryogenesis by using a conditional loss of function
approach. They found that TTF1 function was necessary for
differentiation of specific subtypes of interneurons with early loss
resulting in ectopic production of medium spiny projection neurons
while later loss resulted in near normal levels of cortical interneurons.56
During lung and thyroid development, NKX2.1 binds to the
transcriptional regulatory elements of several proteins, e.g. secretoglo-
bulin 1A and surfactant proteins in the lung and thyroglobulin and
thyroperoxidase in thyroid tissue.57–59 Lung pathology results from
disrupted branching of the bronchial tree during development,
resulting in fewer alveoli, interstitial fibrosis, and cyst-like air spaces.
Thyroid development is frequently interrupted resulting in incomplete
development or agenesis.60
Neuropathology
Two patients with confirmed NKX2.1 mutations have undergone
post-mortem examination, both having died from leukemia. In both,
the gross macroscopic and microscopic appearances were considered
normal.22,38 The original case was reviewed using immunohistochem-
ical staining of striatal tissue, aimed at identifying the neurotransmit-
ters of interneurons whose tangential migration is mediated by TITF1.
This found reduced numbers of striatal interneurons and a reduced
density of calbindin, met-enkephalin, and substance P immunoreactive
fibers, corroborating a number of the findings from the NKX2.1 KO
mouse model.61 These findings also support the idea that NKX2.1
mutation-positive BHC is a developmental disorder, manifesting
during childhood with no further deterioration in adult life. This
may also explain the few available reports of successful treatment are
during childhood and adolescence with minimal change observed
when treating adults.
Conclusion
The clinical features of NKX2.1 BHC have become more clearly
delineated with increased reporting of mutation-positive cases, high-
lighting hypotonia, motor developmental delay, chorea, hypothyroid-
ism, respiratory distress syndrome, and recurrent respiratory tract
infections as the core features of brain–lung–thyroid syndrome. Our
review illustrates that the full triad appears only to be present in
approximately 30% of all mutation-positive cases, and therefore the
absence of one or more disease-associated symptoms should not
discourage genetic testing.
In this review, we have discussed the expanding phenotypic
spectrum associated with NKX2.1 mutations, with some significant
variation from original clinical descriptions. Long considered to be a
disorder in which cognition was preserved, several standardized studies
have now demonstrated that at least a proportion of cases are found to
have reduced IQ. Furthermore, the reported developmental abnorm-
alities of other organ systems (e.g. lung, thyroid, and possibly urinary
tract and musculoskeletal system) provide evidence of the important
role of NKX2.1 in normal development.
Future development of treatment strategies and novel therapies may
also need to consider the role of NKX2.1 in early development.
Symptomatic improvement with levodopa therapy in some cases may
indicate a window of opportunity for treatment in underdeveloped
neuronal networks. Improved understanding of the clinical spectrum
and pathogenic mechanisms governing this condition will require
future multicenter, longitudinal collaborative studies, new laboratory
disease models, development of novel therapeutic approaches, and
large-scale clinical trials.
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